Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Purpose
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced (spread to nearby tissues) or has spread to other parts of the body. To join the study, participants must meet the following conditions: - Be 18 years or older. - Have locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV) squamous or non-squamous NSCLC. - Is not a candidate for complete surgical resection or curative chemoradiotherapy. - Do not have known actionable genomic alterations - Be treatment naïve for advanced or metastatic disease Participants in this study will be assigned to two different parts of the study depending on their type of tumor: participants with squamous NSCLC will be assigned to Part 1, while participants with non-squamous NSCLC will be assigned to Part 2. Each participant will be randomly assigned (like a flip of the coin) to one of two treatment groups in a blinded fashion: - Part 1 - Arm A or Part 2 - Arm C (Experimental Group): Will receive a new study medicine called PF-08634404 along with a kind of chemotherapy specific to the type of tumor. - Part 1 - Arm B or Part 2 - Arm D (Control Group): Will receive an approved medicine called pembrolizumab along with a kind of chemotherapy specific to the type of tumor. Participants will receive their assigned treatment through intravenous (IV) infusions, which means the medicine is given directly into a vein. The treatment will be given in cycles, participants will receive PF-08634404 or Pembrolizumab in combination with chemotherapy followed by maintenance with either PF-08634404 or Pembrolizumab monotherapy (Part 1) or PF-08634404 or Pembrolizumab in combination with a chemotherapeutic drug (Part 2). Participants will continue receiving treatment if it is helping and not experiencing serious side effects. The study will include regular visits for: - Treatment and health checks: while participant continues receiving treatment. - Tests to monitor how cancer responds: every 6 weeks during the first 48 weeks, then every 12 weeks thereafter.
Conditions
- Advanced Non-Small Cell Lung Cancer
- Non-Small Cell Lung Cancer
- Carcinoma, Non-Small-Cell Lung
- Carcinoma, Non-Small-Cell Lung (NSCLC)
- Metastatic Non Small Cell Lung Cancer
- Lung Cancer
Eligibility
- Eligible Ages
- Over 18 Years
- Eligible Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- 18 years of age or older at screening. - Have pathologically confirmed locally advanced (Stage IIIB/IIIC) or metastatic (Stage IV)squamous or non-squamous NSCLC and not be a candidate for complete surgical resection and curative concurrent/sequential chemoradiotherapy (according to the 9th edition of the Union for International Cancer Control and American Joint Committee on Cancer lung cancer Tumor, lymph nodes, metastasis (TNM) staging system). - Have tumor tissue available, either paraffin block or slides from a core, excisional or fine needle biopsy - PD-L1 status available based on local testing results - Measurable disease based on RECIST v1.1 per investigator. - Eastern Cooperative Oncology Group performance status (ECOG) score of 0 or 1 - Expected survival ≥12 weeks
Exclusion Criteria
- Participants with known actionable genomic alteration (AGAs), including estimated glomerular filtration rate (EGFR), anaplastic lymphoma kinase (ALK), Repressor of Silencing 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), v-raf murine sarcoma viral oncogene homolog B1 (BRAF), rearranged during transfection (RET), and mesenchymal-epithelial transition (MET), for which there are available first-line therapies per local standard-of-care (SOC) are ineligible. Documented negative results for EGFR, ALK, and ROS1 AGAs are required for participants with non-squamous histology. - Known active CNS lesions are excluded. Participants with definitively treated brain metastases (surgery and/or radiotherapy) may be eligible. Clinically inactive brain metastases of longest diameter < 1 cm are permitted. - Participants with clinically significant risk of hemorrhage or fistula are excluded. - Participants with any history of another malignancy within 3 years before the first dose of study intervention, or any evidence of residual disease from a previously diagnosed malignancy. - Unresolved toxicities from prior anti-tumor therapy, that did not recover to NCI CTCAE v5.0 Grade 0 or 1. - Known to have a history of a severe allergy to any component of the study intervention, or a history of severe allergic reaction to chimeric or humanized antibody. - History of allogeneic organ / hematopoietic stem cell transplantation. - Participants with any of the following respiratory conditions: - Evidence of noninfectious or drug-induced interstitial lung disease (ILD) or pneumonitis - Grade ≥3 pulmonary disease unrelated to underlying malignancy - History of uncontrolled comorbidities within 6 months prior to the first dose including uncontrolled cardiac and cerebrovascular conditions, hypertension, diabetes, significant vascular disease or arterial/severe venous thromboembolic events. - Major surgery < 4 weeks or minor surgery < 3 days prior to first dose of study intervention. - History of severe bleeding tendency or coagulation dysfunction - History of esophageal varices, severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding within 6 months prior to the first dose. - Participants with acute, chronic or symptomatic infections including participants positive for active HIV, hepatitis B virus (HBV), or Hepatitis C virus (HCV). - Participants with history of immunodeficiency - Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior (in the past 5 years) or laboratory abnormality that may increase the risk of study participation or make the participant inappropriate for the study. - Previous systemic anti-tumor therapy including: 1. Prior systemic therapy, including anti-PD-(L)1 therapy, for locally advanced, unresectable, or metastatic NSCLC. 2. Previous treatment with immunotherapy 3. Prior radiotherapy > 30 Gy to the lung < 6 months of first dose of study intervention 4. Palliative local therapy < 2 weeks before the first dose of study intervention; 5. Non-specific immunomodulatory therapy < 2 weeks before the first dose. 6. Prior systemic anti-angiogenic therapy - Prior immune-related AE that led to anti-PD-(L)1 treatment discontinuation, adverse events from prior immunotherapy not improved to Grade 1 before screening, or required treatment with systemic immunosuppressive therapy. - Prior and concomitant therapy: 1. therapeutic oral or parenteral anticoagulants or thrombolytic agents < 10 days to the first dose. 2. chronic antiplatelet therapy <7 days to randomization. 3. live or attenuated live vaccine < 4 weeks to the first dose. 4. current high-dose systemic corticosteroids. 5. prohibited concomitant medication(s) < 21 days to the first dose. - Breastfeeding participants, participants of childbearing potential, and male participants who are unwilling to follow contraceptive measures.
Study Design
- Phase
- Phase 3
- Study Type
- Interventional
- Allocation
- Randomized
- Intervention Model
- Parallel Assignment
- Primary Purpose
- Treatment
- Masking
- Double (Participant, Investigator)
- Masking Description
- This is double-blind study, neither the participants nor the study team will know whether the participants are receiving PF-08634404 or Pembrolizumab.
Arm Groups
| Arm | Description | Assigned Intervention |
|---|---|---|
|
Experimental Arm A |
Participants will receive PF-08634404 combined with chemotherapy regimen 1, followed by maintenance therapy with PF-08634404. |
|
|
Active Comparator Arm B |
Participants will receive pembrolizumab combined with chemotherapy regimen 1, followed by maintenance therapy with pembrolizumab. |
|
|
Experimental Arm C |
Participants will receive PF-08634404 combined with chemotherapy regimen 2, followed by maintenance therapy with PF-08634404 and chemotherapy. |
|
|
Active Comparator Arm D |
Participants will receive pembrolizumab combined with chemotherapy regimen 2, followed by maintenance therapy with pembrolizumab and chemotherapy. |
|
Recruiting Locations
Pioneer Research Center
Bullhead City, Arizona 86442
Bullhead City, Arizona 86442
Ironwood Cancer & Research Centers
Chandler, Arizona 85224
Chandler, Arizona 85224
Ironwood Cancer & Research Centers
Gilbert, Arizona 85297
Gilbert, Arizona 85297
Ironwood Cancer & Research Centers
Glendale, Arizona 85306
Glendale, Arizona 85306
Ironwood Cancer & Research Centers
Goodyear, Arizona 85395
Goodyear, Arizona 85395
Ironwood Cancer & Research Centers
Mesa, Arizona 85202
Mesa, Arizona 85202
Ironwood Cancer & Research Centers
Mesa, Arizona 85206
Mesa, Arizona 85206
Ironwood Cancer & Research Centers
Phoenix, Arizona 85028
Phoenix, Arizona 85028
Ironwood Cancer & Research Centers
Scottsdale, Arizona 85260
Scottsdale, Arizona 85260
Highlands Oncology Group
Fayetteville, Arkansas 72703
Fayetteville, Arkansas 72703
Highlands Oncology Group
Rogers, Arkansas 72758
Rogers, Arkansas 72758
Highlands Oncology Group
Springdale, Arkansas 72762
Springdale, Arkansas 72762
Oncura Health - Anaheim
Anaheim, California 92805
Anaheim, California 92805
Memorial Care Orange Coast Medical Center Attn
Fountain Valley, California 92708
Fountain Valley, California 92708
MemorialCare Orange Coast Medical Center
Fountain Valley, California 92708
Fountain Valley, California 92708
OC Blood and Cancer Care
Fountain Valley, California 92708
Fountain Valley, California 92708
Oncura Health - Fountain Valley
Fountain Valley, California 92708
Fountain Valley, California 92708
Oncura Health - Corporate (Central IDS & Regulatory Only)
Glendale, California 91204
Glendale, California 91204
Memorial Care Saddleback Medical Center Attn
Laguna Hills, California 92653
Laguna Hills, California 92653
Stockton Hematology Oncology Medical Group
Lodi, California 95242
Lodi, California 95242
Memorial Care Long Beach Medical Center
Long Beach, California 90806
Long Beach, California 90806
Oncura Health - Good Samaritan
Los Angeles, California 90017
Los Angeles, California 90017
Stockton Hematology Oncology Medical Group
Manteca, California 95336
Manteca, California 95336
Stockton Hematology Oncology Medical Group
Modesto, California 95350
Modesto, California 95350
Oncura Health - Riverside
Riverside, California 92501
Riverside, California 92501
Sansum Clinic
Santa Barbara, California 93105
Santa Barbara, California 93105
Sansum Clinic
Solvang, California 93463
Solvang, California 93463
Stockton Hematology Oncology Group
Stockton, California 95204
Stockton, California 95204
Stockton Hematology Oncology Medical Group
Tracy, California 95377
Tracy, California 95377
Oncura Health - Valley Presbyterian
Van Nuys, California 91405
Van Nuys, California 91405
Florida Cancer Specialists
Bonita Springs, Florida 34135
Bonita Springs, Florida 34135
Florida Cancer Specialists
Bradenton, Florida 34211
Bradenton, Florida 34211
Florida Cancer Specialists
Cape Coral, Florida 33909
Cape Coral, Florida 33909
Florida Cancer Specialists
Clearwater, Florida 33761
Clearwater, Florida 33761
BRCR Global- Coral Springs
Coral Springs, Florida 33065
Coral Springs, Florida 33065
Florida Cancer Specialists
Daytona Beach, Florida 32117
Daytona Beach, Florida 32117
Cancer Specialists of North Florida
Fleming Island, Florida 32003
Fleming Island, Florida 32003
Florida Cancer Specialists
Fleming Island, Florida 32003
Fleming Island, Florida 32003
Helios Clinical Research
Fort Lauderdale, Florida 33316
Fort Lauderdale, Florida 33316
Florida Cancer Specialists - South
Fort Myers, Florida 33901
Fort Myers, Florida 33901
Florida Cancer Specialists
Fort Myers, Florida 33905
Fort Myers, Florida 33905
Florida Cancer Specialists
Fort Myers, Florida 33908
Fort Myers, Florida 33908
Florida Cancer Specialists
Gainesville, Florida 32605
Gainesville, Florida 32605
Cancer Specialists of North Florida
Jacksonville, Florida 32204
Jacksonville, Florida 32204
Cancer Specialists of North Florida
Jacksonville, Florida 32218
Jacksonville, Florida 32218
Cancer Specialists of North Florida
Jacksonville, Florida 32256
Jacksonville, Florida 32256
Cancer Specialists of North Florida
Jacksonville, Florida 32258
Jacksonville, Florida 32258
Florida Cancer Specialists
Largo, Florida 33770
Largo, Florida 33770
Florida Cancer Specialists
Lecanto, Florida 34461
Lecanto, Florida 34461
Florida Cancer Specialists
N. Venice, Florida 34275
N. Venice, Florida 34275
Florida Cancer Specialists
Naples, Florida 34102
Naples, Florida 34102
Cancer Specialists of North Florida
Neptune Beach, Florida 32266
Neptune Beach, Florida 32266
Florida Cancer Specialists
Ocala, Florida 34474
Ocala, Florida 34474
Alpha Clinical Research Centers LLC
Orange City, Florida 32763
Orange City, Florida 32763
Florida Cancer Specialists
Orange City, Florida 32763
Orange City, Florida 32763
Mid Florida Hematology and Oncology Center
Orange City, Florida 32763
Orange City, Florida 32763
Florida Cancer Specialists
Orlando, Florida 32806
Orlando, Florida 32806
Orlando Health Ambulatory Care Center
Orlando, Florida 32806
Orlando, Florida 32806
Orlando Health Cancer Institute
Orlando, Florida 32806
Orlando, Florida 32806
Orlando Health Orlando Regional Medical Center
Orlando, Florida 32806
Orlando, Florida 32806
Cancer Care Centers of Brevard, Inc.
Palm Bay, Florida 32901
Palm Bay, Florida 32901
Florida Cancer Specialists
Palm Beach Gardens, Florida 33410
Palm Beach Gardens, Florida 33410
Florida Cancer Specialists
Port Charlotte, Florida 33980
Port Charlotte, Florida 33980
Hematology Oncology Associates of the Treasure Coast
Port Saint Lucie, Florida 34952
Port Saint Lucie, Florida 34952
Cancer Specialists of North Florida
Saint Augustine, Florida 32086
Saint Augustine, Florida 32086
Florida Cancer Specialists
Sarasota, Florida 34236
Sarasota, Florida 34236
Florida Cancer Specialists
Sebring, Florida 33870
Sebring, Florida 33870
Florida Cancer Specialists
St. Petersburg, Florida 33701
St. Petersburg, Florida 33701
Florida Cancer Specialists
St. Petersburg, Florida 33705
St. Petersburg, Florida 33705
Florida Cancer Specialists
Tallahassee, Florida 32308
Tallahassee, Florida 32308
BRCR Medical Center Inc.
Tamarac, Florida 33321
Tamarac, Florida 33321
Florida Cancer Specialists
Tampa, Florida 33607
Tampa, Florida 33607
Florida Cancer Specialists
Tavares, Florida 32778
Tavares, Florida 32778
Florida Cancer Specialists
The Villages, Florida 32159
The Villages, Florida 32159
Florida Cancer Specialists
Trinity, Florida 34655
Trinity, Florida 34655
Florida Cancer Specialists
Wellington, Florida 33414
Wellington, Florida 33414
Florida Cancer Specialists - East
West Palm Beach, Florida 33401
West Palm Beach, Florida 33401
Florida Cancer Specialists
Winter Park, Florida 32789
Winter Park, Florida 32789
Illinois Cancer Specialists
Arlington Heights, Illinois 60005
Arlington Heights, Illinois 60005
Illinois CancerCare - Bloomington
Bloomington, Illinois 61704
Bloomington, Illinois 61704
University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center)
Chicago, Illinois 60612
Chicago, Illinois 60612
University of Illinois Hospital and Health Sciences System
Chicago, Illinois 60612
Chicago, Illinois 60612
Illinois CancerCare - Galesburg
Galesburg, Illinois 61401
Galesburg, Illinois 61401
Hope and Healing Cancer Services
Hinsdale, Illinois 60521
Hinsdale, Illinois 60521
Hope and Healing Cancer Services
New Lenox, Illinois 60451
New Lenox, Illinois 60451
Illinois CancerCare-Ottawa-Fox River Cancer Center
Ottawa, Illinois 61350
Ottawa, Illinois 61350
Illinois CancerCare-Pekin
Pekin, Illinois 61554
Pekin, Illinois 61554
Illinois CancerCare, P.C.
Peoria, Illinois 61615
Peoria, Illinois 61615
Illinois CancerCare-Peru - Valley Regional Cancer Center
Peru, Illinois 61354
Peru, Illinois 61354
Illinois CancerCare-Washington
Washington, Illinois 61571
Washington, Illinois 61571
Pontchartrain Cancer Center
Covington, Louisiana 70433
Covington, Louisiana 70433
Pontchartrain Cancer Center
Hammond, Louisiana 70403
Hammond, Louisiana 70403
Maryland Oncology Hematology, P.A.
Annapolis, Maryland 21401
Annapolis, Maryland 21401
Maryland Oncology Hematology, P.A.
Bethesda, Maryland 20817
Bethesda, Maryland 20817
Maryland Oncology Hematology, P.A.
Brandywine, Maryland 20613
Brandywine, Maryland 20613
Maryland Oncology Hematology - Columbia
Columbia, Maryland 21044
Columbia, Maryland 21044
Maryland Oncology Hematology, P.A.
Germantown, Maryland 20876
Germantown, Maryland 20876
Maryland Oncology Hematology, P.A.
Largo, Maryland 20774
Largo, Maryland 20774
Maryland Oncology Hematology, P.A.
Rockville, Maryland 20850
Rockville, Maryland 20850
Maryland Oncology Hematology, P.A.
Silver Spring, Maryland 20904
Silver Spring, Maryland 20904
Minnesota Oncology Hematology, P.A.
Burnsville, Minnesota 55337
Burnsville, Minnesota 55337
Minnesota Oncology Hematology, P.A.
Chaska, Minnesota 55318
Chaska, Minnesota 55318
Minnesota Oncology Hematology, P.A.
Coon Rapids, Minnesota 55433
Coon Rapids, Minnesota 55433
Minnesota Oncology Hematology, P.A.
Edina, Minnesota 55435
Edina, Minnesota 55435
Minnesota Oncology Hematology, P.A.
Maple Grove, Minnesota 55369
Maple Grove, Minnesota 55369
Minnesota Oncology Hematology, P.A.
Maplewood, Minnesota 55109
Maplewood, Minnesota 55109
Minnesota Oncology Hematology, P.A.
Woodbury, Minnesota 55125
Woodbury, Minnesota 55125
Hattiesburg Clinic Hematology/Oncology
Hattiesburg, Mississippi 39401
Hattiesburg, Mississippi 39401
NHO Revive Research Institute, LLC
Lincoln, Nebraska 68506
Lincoln, Nebraska 68506
NHO Support Center
Lincoln, Nebraska 68506
Lincoln, Nebraska 68506
Cancer Partners of Nebraska
Lincoln, Nebraska 68516
Lincoln, Nebraska 68516
New York Oncology Hematology
Albany, New York 12206
Albany, New York 12206
New York Oncology Hematology
Clifton Park, New York 12065
Clifton Park, New York 12065
Hematology Oncology Associates of Rockland
Nyack, New York 10960
Nyack, New York 10960
FirstHealth Cancer Center
Pinehurst, North Carolina 28374
Pinehurst, North Carolina 28374
FirstHealth Moore Regional Hospital
Pinehurst, North Carolina 28374
Pinehurst, North Carolina 28374
Carolina Cancer Research Center
Wilson, North Carolina 27893
Wilson, North Carolina 27893
Oncology Hematology Care Clinical Trials
Cincinnati, Ohio 45211
Cincinnati, Ohio 45211
Oncology Hematology Care Clinical Trials
Cincinnati, Ohio 45242
Cincinnati, Ohio 45242
Oncology Hematology Care Clinical Trials
Cincinnati, Ohio 45245
Cincinnati, Ohio 45245
University Hospitals Cleveland Medical Center
Cleveland, Ohio 44106
Cleveland, Ohio 44106
Oncology Hematology Care Clinical Trials
Fairfield, Ohio 45014
Fairfield, Ohio 45014
Northwest Cancer Specialists, P.C
Happy Valley, Oregon 97015
Happy Valley, Oregon 97015
Northwest Cancer Specialists, P.C.
Portland, Oregon 97227
Portland, Oregon 97227
Northwest Cancer Specialists, P.C
Tigard, Oregon 97223
Tigard, Oregon 97223
Tennessee Oncology, PLLC - Chattanooga Downtown
Chattanooga, Tennessee 37403
Chattanooga, Tennessee 37403
Tennessee Oncology, PLLC - Chattanooga - Medical Park II
Chattanooga, Tennessee 37404
Chattanooga, Tennessee 37404
Tennessee Oncology, PLLC - Franklin
Franklin, Tennessee 37067
Franklin, Tennessee 37067
Tennessee Oncology, PLLC - Gallatin
Gallatin, Tennessee 37066
Gallatin, Tennessee 37066
Tennessee Cancer Specialists Dowell Springs location
Knoxville, Tennessee 37909
Knoxville, Tennessee 37909
University of Tennessee Medical Center
Knoxville, Tennessee 37920
Knoxville, Tennessee 37920
Tennessee Cancer Specialists - Parkwest Location
Knoxville, Tennessee 37932
Knoxville, Tennessee 37932
Tennessee Oncology, PLLC - Lebanon
Lebanon, Tennessee 37090
Lebanon, Tennessee 37090
Tennesseee Oncology, PLLC - Mount Juliet
Mount Juliet, Tennessee 37122
Mount Juliet, Tennessee 37122
Tennessee Oncology, PLLC - Murfreesboro
Murfreesboro, Tennessee 37129
Murfreesboro, Tennessee 37129
SCRI Oncology Partners
Nashville, Tennessee 37203
Nashville, Tennessee 37203
Tennessee Oncology, PLLC-Elliston Place Plaza Medical Oncology &Hematology
Nashville, Tennessee 37203
Nashville, Tennessee 37203
Tennessee Oncology, PLLC - Saint Thomas West
Nashville, Tennessee 37205
Nashville, Tennessee 37205
Tennessee Oncology, PLLC -Shelbyville
Shelbyville, Tennessee 37160
Shelbyville, Tennessee 37160
Texas Oncology - West Texas
Abilene, Texas 79606
Abilene, Texas 79606
Texas Oncology - Northeast Texas
Allen, Texas 75013
Allen, Texas 75013
Texas Oncology - West Texas
Amarillo, Texas 79124
Amarillo, Texas 79124
Texas Oncology - DFW
Arlington, Texas 76012
Arlington, Texas 76012
Texas Oncology - DFW
Arlington, Texas 76014
Arlington, Texas 76014
Texas Oncology - Central/South Texas
Austin, Texas 78758
Austin, Texas 78758
Texas Oncology - Gulf Coast
Beaumont, Texas 77702
Beaumont, Texas 77702
Texas Oncology - DFW
Bedford, Texas 76022
Bedford, Texas 76022
Texas Oncology - DFW
Dallas, Texas 75203
Dallas, Texas 75203
Texas Oncology - DFW
Dallas, Texas 75230
Dallas, Texas 75230
Texas Oncology - DFW
Dallas, Texas 75231
Dallas, Texas 75231
Texas Oncology - DFW
Dallas, Texas 75237
Dallas, Texas 75237
Texas Oncology - DFW
Dallas, Texas 75246
Dallas, Texas 75246
Texas Oncology - Northeast Texas
Denison, Texas 75020
Denison, Texas 75020
Texas Oncology - Northeast Texas
Denton, Texas 76201
Denton, Texas 76201
Texas Oncology - West Texas
El Paso, Texas 79902
El Paso, Texas 79902
Texas Oncology - West Texas
El Paso, Texas 79915
El Paso, Texas 79915
Texas Oncology - West Texas
El Paso, Texas 79938
El Paso, Texas 79938
Texas Oncology - Northeast Texas
Flower Mound, Texas 75028
Flower Mound, Texas 75028
Texas Oncology - DFW
Fort Worth, Texas 76104
Fort Worth, Texas 76104
Texas Oncology - DFW
Grapevine, Texas 76051
Grapevine, Texas 76051
Texas Oncology - Central/South Texas
Harlingen, Texas 78550
Harlingen, Texas 78550
Texas Oncology - Gulf Coast
Houston, Texas 77024
Houston, Texas 77024
Texas Oncology - Gulf Coast
Houston, Texas 77054
Houston, Texas 77054
Texas Oncology - Gulf Coast
Houston, Texas 77070
Houston, Texas 77070
Texas Oncology - Gulf Coast
Humble, Texas 77338
Humble, Texas 77338
US Oncology Investigational Products Center (IPC)
Irving, Texas 75063
Irving, Texas 75063
US Oncology Investigational Products Center
Irving, Texas 75063
Irving, Texas 75063
Texas Oncology - Northeast Texas
Lewisville, Texas 75056
Lewisville, Texas 75056
Texas Oncology - Northeast Texas
Longview, Texas 75601
Longview, Texas 75601
Texas Oncology - Central/South Texas
McAllen, Texas 78503
McAllen, Texas 78503
Texas Oncology - Northeast Texas
McKinney, Texas 75071
McKinney, Texas 75071
Texas Oncology - West Texas
Midland, Texas 79701
Midland, Texas 79701
Texas Oncology - West Texas
Odessa, Texas 79761
Odessa, Texas 79761
Texas Oncology - Northeast Texas
Palestine, Texas 75801
Palestine, Texas 75801
Texas Oncology - Northeast Texas
Paris, Texas 75460
Paris, Texas 75460
Texas Oncology - Gulf Coast
Pearland, Texas 77584
Pearland, Texas 77584
Texas Oncology - DFW
Plano, Texas 75075
Plano, Texas 75075
Texas Oncology - DFW
Plano, Texas 75093
Plano, Texas 75093
Texas Oncology - Gulf Coast
Sugar Land, Texas 77479
Sugar Land, Texas 77479
Texas Oncology - Gulf Coast
The Woodlands, Texas 77380
The Woodlands, Texas 77380
Texas Oncology - Northeast Texas
Tyler, Texas 75702
Tyler, Texas 75702
Texas Oncology - Central/South Texas
Waco, Texas 76712
Waco, Texas 76712
Texas Oncology - Gulf Coast
Webster, Texas 77598
Webster, Texas 77598
Texas Oncology - Central/South Texas
Weslaco, Texas 78596
Weslaco, Texas 78596
Texas Oncology - West Texas
Wichita Falls, Texas 76310
Wichita Falls, Texas 76310
Huntsman Cancer Institute, University of Utah
Salt Lake City, Utah 84112
Salt Lake City, Utah 84112
UVA Comprehensive Cancer Center
Charlottesville, Virginia 22903
Charlottesville, Virginia 22903
UVA Health Fontaine Research Park
Charlottesville, Virginia 22903
Charlottesville, Virginia 22903
University of Virginia
Charlottesville, Virginia 22908
Charlottesville, Virginia 22908
UVA Health Cancer Care Pantops
Charlottesville, Virginia 22911
Charlottesville, Virginia 22911
Northwest Cancer Specialists, P.C.
Vancouver, Washington 98684
Vancouver, Washington 98684
Minnesota Oncology Hematology, P.A.
Hudson, Wisconsin 54016
Hudson, Wisconsin 54016
Pan American Center for Oncology Trials, LLC- Dorado Office
Dorado, Puerto Rico 00646
Dorado, Puerto Rico 00646
Pan American Center for Oncology Trials, LLC - Manati Office
Manati, Puerto Rico 00674
Manati, Puerto Rico 00674
Pan American Center for Oncology Trials, LLC - Mayaguez Office
Mayagüez, Puerto Rico 00680
Mayagüez, Puerto Rico 00680
BRCR Global Puerto Rico - Hato Rey
San Juan, Puerto Rico 00917
San Juan, Puerto Rico 00917
More Details
- Status
- Recruiting
- Sponsor
- Pfizer